NCT05134974 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) | Biotech Hunter

Enrollment

368

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

March 18, 2022

Study Completion Date

March 29, 2022

Conditions

MydriasisDilation

Interventions

DRUG

Phentolamine Ophthalmic Solution 0.75%

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

DRUG

Phentolamine Ophthalmic Solution Vehicle

Trial Locations (15)

17349

Clinical Site 14, Shrewsbury

27529

Clinical Site 15, Garner

30009

Clinical Site 1, Roswell

30260

Clinical Site 6, Morrow

32779

Clinical Site 8, Longwood

33484

Clinical Site 9, Delray Beach

38119

Clinical Site 3, Memphis

45701

Clinical Site 4, Athens

55420

Clinical Site 2, Bloomington

57101

Clinical Site 11, Sioux Falls

60046

Clinical Site 13, Lake Villa

66762

Clinical Site 5, Pittsburg

92655

Clinical Site 12, Westminster

92663

Clinical Site 10, Newport Beach

02888

Clinical Site 7, Warwick